Innovaderm Receives Top Recognition in the CRO Leadership Awards
Innovaderm today announced it has been awarded the CRO Leadership Awards. This huge achievement testifies to the excellency and ever-growing presence in the CRO world.
Innovaderm is offering full-service clinical research services, while serving its partners in their journey to discover new dermatology therapies.
Being selected by sponsors as top award winner in the Capabilities category, Innovaderm proves once more being top of mind for drug developers when it comes to selecting a CRO for their phase 1 to 3 with sites in North America and Europe. Other categories where Innovaderm performed in the top are: Expertise, Compatibility, Quality and Reliability.
"These award winners have proven themselves to be the top service providers in each category, said Ed Miseta, chief editor for Clinical Leader. "I congratulate all of them for work ethic they exhibit in consistently meeting the needs of their drug development clients."
The CRO Leadership Awards honours clinical research organizations that meet and exceed customer expectations. For 2021, Clinical Leader and Life Science Leader have once again teamed up with Industry Standard Research (ISR) to determine the winners. Recipients of the awards are vetted against more than 60 CROs and the participants are assessed by sponsor decision makers who have used clinical research services within the past 18 months.
Dr. Robert Bissonnette, Founder and CEO of Innovaderm, commented: “We are very pleased to receive this recognition. It is a tremendous honour to see our work acknowledged by Biotech and Pharma sponsors. At Innovaderm, we pride ourselves in offering niche expertise and quality services and these awards demonstrate that we are able to deliver.”
About Innovaderm
Innovaderm is a full-service contract research organization (CRO) offering support in the management of Phase 1 to 3 trials worldwide. Innovaderm partners with the drug industry to support single and multicenter clinical research & development. For the past 20 years, our team has supported sponsors with their medical, scientific and clinical execution in dermatology trials. To learn more about Innovaderm, please visit us on our website, LinkedIn, or Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210706005089/en/
Contact information
Audrey Miron
Innovaderm Research
1-866-575-3111 ext. 274
amiron@innovaderm.com
About Business Wire
Business WireSubscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lenovo Embraces the AI PC Era with New ThinkCentre Desktops Powered by AMD Ryzen PRO 8000 Series Desktop Processors16.4.2024 15:00:00 CEST | Press release
Lenovo™ has unveiled a selection of ThinkCentre™ desktops powered by AMD Ryzen™ PRO 8000 Series desktop processors with up to 16 TOPS (trillion operations per second) of integrated NPU capability dedicated to process AI workloads, including the performance focused ThinkCentre M75t Gen 5, the flexible ThinkCentre M75s Gen 5, and the compact ThinkCentre M75q Gen 5. Designed to meet the diverse needs of modern business, the ThinkCentre M75 Gen 5 family of desktops harnesses the AI capability of its component while optimizing its energy efficiency to deliver impressive results. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416990902/en/ Lenovo ThinkCentre M75s Gen 5 (Photo: Business Wire) “The AI PC era is already here and at Lenovo we are embracing it to unlock new possibilities,” said Sanjeev Menon, vice president and general manager, Worldwide Desktop Business in Intelligent Devices Group, Lenovo. “The need for businesses
Dave & Buster’s International Cements Its Presence in the APAC Region16.4.2024 15:00:00 CEST | Press release
Dave & Buster's Entertainment, Inc., the ultimate destination for food, drink and entertainment is delighted to announce its latest franchise agreement furthering the brands development in APAC. Dave & Buster’s has finalized a deal to open five new stores in the Philippines, raising the international development store count to 38. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416173901/en/ Antonio Bautista, Chief International Development Officer of Dave & Buster’s and Paul Manuud, President of The Bistro Group (Photo: Business Wire) Antonio Bautista, Chief International Development Officer at Dave & Buster’s, stated "We are thrilled to announce our expansion into the Philippines, marking another significant milestone in our global growth strategy. Our partnership with The Bistro Group in the Philippines aligns with our mission to deliver exceptional 'Eat, Drink, Play, and Watch' experiences to a broader audience. The Bi
Laserfiche Reimagines Partner Ecosystem to Empower Solution Providers Worldwide16.4.2024 15:00:00 CEST | Press release
Laserfiche — the leading SaaS provider of intelligent content management and business process automation — has announced a number of channel momentum milestones as the organization marks the start of a new era of growth and technology innovation. In 2024, the company is strengthening its partner ecosystem to deliver more ways for organizations to transform the way they manage content, automate workflows and accelerate how business gets done. “We’ve seen incredible progress across all areas of Laserfiche over the past year, including growth into emerging industries and regions, increased investment into our channel program and resources, and hiring of key leaders,” said Laserfiche CEO Karl Chan. “In 2024, we look forward to building on this momentum, continuing to strengthen our partner ecosystem and bringing even more solutions to market that empower organizations and inspire the world.” Expanding Global Footprint Over the past year, Laserfiche saw widespread adoption of digital transf
Experian Named a Leader in IDC MarketScape: Worldwide Enterprise Fraud Solutions 2024 Vendor Assessment16.4.2024 15:00:00 CEST | Press release
Experian announced that the company was named a Leader in the IDC MarketScape: Worldwide Enterprise Fraud Solutions 2024 Vendor Assessment (doc #US51939124, March 2024). The report evaluates each vendor’s advanced fraud detection capabilities, alignment with customer needs, and future strategy and roadmap for innovation. Experian offers an integrated digital identity and fraud risk platform that delivers analytics-driven outcomes through sophisticated orchestration. The IDC MarketScape report noted, “In addition to evaluating the transactional data for potential fraud, Experian's CrossCore solution includes identity-authentication tools. The solution uses identity data, device intelligence, email and phone intelligence, alternative identity data, biometrics, behavioral biometrics, one-time passwords, and document verification to confirm identities and aid with identity protection, including synthetic identity protection. Experian utilizes multiple data partnerships in its fraud solutio
Merck Launches First All-in-One Genetic Stability Assay to Accelerate Biosafety Testing16.4.2024 14:00:00 CEST | Press release
Merck, a leading science and technology company, has launched the first all-in-one, validated genetic stability assay of its kind. The Aptegra™ CHO genetic stability assay leverages whole genome sequencing and bioinformatics to significantly accelerate biosafety testing for clients and therefore, their move into commercial production. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416870388/en/ A scientist preparing samples in the next-generation sequencing laboratory at Merck’s Rockville, Maryland, USA site. (Photo: Business Wire) “Driving innovation in biosafety testing is essential to bringing new therapies to patients faster,” said Benjamin Hein, Head of Life Science Services, Life Science business of Merck. “CHO genetic stability testing has remained relatively unchanged for many years. The Aptegra™ platform transforms biosafety testing with a digital solution using next-generation sequencing.” Currently, FDA guidanc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom